Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
3,625 SEK | -3,85 % | -3,33 % | -9,60 % |
13/06 | Transcript : Saniona AB - Special Call | |
29/05 | Saniona AB (publ) publie ses resultats pour le premier trimestre clos le 31 mars 2024 | CI |
Métier
Nombre d'employés: 23
Ventes par activité
SEK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 15 | 100,0 % | 17 | 100,0 % | +10,19 % |
Ventes par région
SEK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Germany
51,8
%
| - | - | 9 | 51,8 % | - |
United Kingdom
44,5
%
| - | - | 7 | 44,5 % | - |
Denmark
3,8
%
| - | - | 1 | 3,8 % | - |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Founder | 66 | 01/01/11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01/01/11 |
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01/01/14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01/05/20 | |
Corporate Officer/Principal | 52 | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Director/Board Member | 66 | 01/01/15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19/01/18 |
Director/Board Member | 58 | 01/01/23 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 111 238 252 | 80 683 943 ( 72,53 %) | 0 | 72,53 % |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Secteur
Ventes par région
Bénéfices annuels - Taux de surprise
Varia. 1 janv. | Capi. | |
---|---|---|
-9,60 % | 39,87 M | |
+16,49 % | 122 Md | |
+21,73 % | 116 Md | |
+22,18 % | 27,03 Md | |
-21,81 % | 20,36 Md | |
-16,89 % | 16,43 Md | |
-18,81 % | 15,91 Md | |
-44,74 % | 15,6 Md | |
+62,72 % | 14,94 Md | |
+3,09 % | 13,59 Md |
- Bourse
- Actions
- Action SANION
- Société SANA AB